Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.52 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | ILK | Q13418 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | SCN4A | P35499 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NCS1 | P62166 | 1/20 | 0.42 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30602944 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2NPSR1ALOX5DYRK1APPARA | |
| SCHEMBL2707227 | 0.87 | PPARA (0.63) | SMN1; SMN2NPSR1DYRK1APPARAKEAP1 | |
| SCHEMBL17153983 | 0.87 | ALOX5 (0.52) | SMN1; SMN2NPSR1ALOX5DYRK1APPARA | |
| SCHEMBL13483968 | 0.85 | SMN1; SMN2 (0.61) | SMN1; SMN2NPSR1ALOX5PPARAKEAP1 | |
| SCHEMBL17153808 | 0.82 | ALOX5 (0.49) | SMN1; SMN2NPSR1ALOX5DYRK1APPARA | |
| SCHEMBL10761623 | 0.81 | DYRK1A (0.60) | ALOX5DYRK1APPARAILKCYP1A2 | |
| SCHEMBL9393819 | 0.79 | ALOX5 (0.61) | SMN1; SMN2ALOX5DYRK1APPARAILK | |
| SCHEMBL1512366 | 0.78 | SMN1; SMN2 (0.65) | SMN1; SMN2NPSR1DYRK1APPARAKEAP1 | |
| SCHEMBL30602942 | 0.78 | SMN1; SMN2 (0.65) | SMN1; SMN2NPSR1DYRK1APPARAKEAP1 | |
| SCHEMBL9853857 | 0.78 | POLB (0.56) | SMN1; SMN2ALOX5DYRK1AILKEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116926578-A | Method for synthesizing heteroaryl thiophenol | 新疆大学 | 2023-10-24 | — | — | CN | disclosed |
| US-11535607-B2 | Isoindolines as HDAC inhibitors | VALO HEALTH, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-20210253555-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO EARLY DISCOVERY, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| EP-2234999-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009080533-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080533-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
| US-5108887-A | Zeromethine merocyanine dyes as J-aggregating spectral sensitizers for tabular emulsions | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535607-B2 | Isoindolines as HDAC inhibitors | HDAC1, HDAC2, HDAC3 | SMN1; SMN2 3655/4885NPSR1 2275/4885ALOX5 4365/4885 |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, MTNR1A | SMN1; SMN2 2577/4885NPSR1 12/4885ALOX5 272/4885 |
| US-20210253555-A1 | ISOINDOLINES AS HDAC INHIBITORS | HDAC1, HDAC2, HDAC3 | SMN1; SMN2 3655/4885NPSR1 2275/4885ALOX5 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.